-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 25, 2022, Beijing time, the journal Nature Structural & Molecular Biologypublished online the latest achievements of the Shenzhen University of Technology (tentative name, hereinafter referred to as "Shenzhen Science and Technology") Ye Keqiang's team and the Wuhan University People's Hospital Zhang Zhentao's team
Screenshot of the paper online
AD is the most common neurodegenerative disease in clinic, and abnormal aggregation of tau protein in the brain is an important pathological manifestation of AD
The research team has conducted a long-term exploration of the molecular mechanism of Tau protein aggregation in the brain
Next, the team found that ApoE3 binds to Tau and reduces cleavage of Tau by AEP, but the AD-associated allele, ApoE4, loses the ability to bind Tau protein, making Tau more susceptible to cleavage by AEP
In the newly published study, the team further studied the modification effect of DOPAGEL on Tau and found that DOPAGEL can directly covalently modify the K353 site of Tau.
The significance of this study is to reveal why the Tau protein in the locus coeruleus first aggregates to form pathological inclusion bodies during the pathogenesis of AD, which is very important for understanding the initiation and dissemination of Tau protein aggregates in the brain of AD patients.
Professor Ye Keqiang is the dean of the Department of Biology at the School of Life and Health of Shenyang Polytechnic, and was a tenured professor at Emory University in the United States
Original link: https://
Figure 1: DOPAGEL promotes intracellular Tau aggregation while K353R mutation can block DOPEGAL's promotion
Figure 2: Blocking the modification of Tau by DOPEGAL can delay the aggregation of Tau.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
|